Flash Finance

Zenith Drugs LimitedZENITHDRUGCorporate

Pharmaceuticals - Indian - Formulations Latest results: Mar 2026 6 quarters of data
₹40.00
MCap ₹69 Cr · P/E 17.1
Zenith Drugs Limited — Stock analysis & AI research Zenith Drugs Limited — Seasonality — best & worst months Zenith Drugs Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹93 Cr
Sales · Mar 2026
+40.9% YoY
₹6 Cr
Operating Profit · Mar 2026
-14.3% YoY
6.5%
OPM % · Mar 2026
-38.7% YoY
₹2 Cr
Net Profit · Mar 2026
+100.0% YoY
₹0.94
EPS · Mar 2026
+11.9% YoY

📝 Zenith Drugs Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Zenith Drugs Limited reported revenue of ₹93 crore for the quarter ended March 2026 (Q4 FY26), up 40.9% from ₹66 crore in the same quarter last year.

Net profit rose 100.0% year-on-year to ₹2 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹0.94.

Operating profit stood at ₹6 crore — an operating margin (OPM) of 6.5%, compared with 10.6% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹171 crore with a net profit of ₹4 crore.

Valuation snapshot

At the current price of ₹40.00, ZENITHDRUG has a market capitalisation of ₹69 crore and a trailing P/E of about 17.1.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 17th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 69.98%, foreign institutional investors (FIIs) 0.00%, domestic institutional investors (DIIs) 0.00%, public shareholders 30.02% of Zenith Drugs Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹69 Cr
Current Price ?
₹40.0
P/E ?
17.15below ind
Industry P/E ?
21.30
P/B ?
0.91
P/S ?
0.40
P/FCF ?
-13.72
Enterprise Value ?
₹124 Cr
EV/EBITDA ?
10.30
PEG ?
N/A
Earnings Yield ?
4.9%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹171 Cr
OPM ?
7.0%
Profit after tax (TTM) ?
₹4 Cr
EPS (TTM) ?
₹2.33
ROCE ?
9.0%
ROE ?
5.3%
ROA ?
2.1%
Growth
Sales — latest qtr ?
₹93 Cr
PAT — latest qtr ?
₹2 Cr
YoY qtr sales growth ?
40.9%
YoY qtr profit growth ?
100.0%
Sales growth (3y) ?
14%
Sales growth (5y) ?
19%
Profit growth (3y) ?
-5%
Profit growth (5y) ?
6%
Financial Health
Debt ?
₹55 Cr
Debt to Equity ?
0.73
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
69.98%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-21.6%
Return 6 months ?
-9.4%

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026 YoY % QoQ %
Sales 696268667893 +40.9% —
Operating Profit 1167766 -14.3% —
Other Income -121123 +200.0% —
Interest 121233 +50.0% —
Depreciation 111233 +50.0% —
Profit Before Tax 866423 -25.0% —
Net Profit 646122 +100.0% —
EPS 4.752.243.340.841.360.94 +11.9% —
OPM % 15.9% 9.7% 10.3% 10.6% 7.7% 6.5% -38.7% —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 0.40171717 +0.0%
Reserves 17455258 +11.5%
Borrowings 25244955 +12.2%
Other Liabilities 54484457 +29.5%
Total Liabilities 97134161188 +16.8%
Fixed Assets 11114041 +2.5%
CWIP 04310 +233.3%
Investments 0000 —
Other Assets 86119118136 +15.3%
Total Assets 97134161188 +16.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -4-16-59 +280.0%
Cash from Investing Activity -2-5-31-14 +54.8%
Cash from Financing Activity 630285 -82.1%
Net Cash Flow -09-80 +100.0%
Free Cash Flow -6-21-37-5 +86.5%
CFO/OP -27%-70%-25%86% +444.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 157188167156 -6.6%
Inventory Days —249277126 -54.5%
Days Payable —412281166 -40.9%
Cash Conversion Cycle 15725163117 -28.2%
Working Capital Days 391119877 -21.4%
ROCE % 25%28%13%9% -30.8%

👥 Shareholding (latest 4 periods)

Metric Sep 2024Mar 2025Sep 2025Mar 2026 % Chg
Promoters 69.98%69.98%69.98%69.98% +0.0%
FIIs 0.42%0.06%0.00%0.00% —
DIIs 0.00%0.00%0.00%0.00% —
Public 29.60%29.96%30.02%30.02% +0.0%
No. of Shareholders 1,3551,5441,4661,435 -2.1%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Zenith Drugs Limited's revenue in Q4 FY26?
Zenith Drugs Limited reported revenue of ₹93 crore for the quarter ended March 2026 (Q4 FY26), up 40.9% from ₹66 crore in the same quarter last year.
What was Zenith Drugs Limited's net profit in Q4 FY26?
Net profit rose 100.0% year-on-year to ₹2 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹0.94.
What is ZENITHDRUG's market capitalisation and P/E ratio?
At the current price of ₹40.00, ZENITHDRUG has a market capitalisation of ₹69 crore and a trailing P/E of about 17.1.
Who owns Zenith Drugs Limited? (shareholding pattern)
As of Mar 2026, promoters held 69.98%, foreign institutional investors (FIIs) 0.00%, domestic institutional investors (DIIs) 0.00%, public shareholders 30.02% of Zenith Drugs Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI